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Background and Purpose—Transient ischemic attack (TIA) patients are at risk of recurrent vascular events. The primary
objectives were to evaluate among TIA patients the prevalence of sleep apnea and among patients with sleep apnea
auto-titrating continuous positive airway pressure (auto-CPAP) adherence. The secondary objective was to describe
among TIA patients with sleep apnea the recurrent vascular event rate by auto-CPAP use category.
Methods—All intervention patients received auto-CPAP for 2 nights, but only intervention patients with evidence of sleep
apnea received auto-CPAP for the remainder of the 90-day period. Intervention patients received polysomnography at
90 days after TIA. Control patients received polysomnography at baseline and at 90 days. Acceptable auto-CPAP
adherence was defined as 4 hours per night for 75% of nights. Vascular events included recurrent TIA, stroke,
hospitalization for congestive heart failure, myocardial infarction, or death.
Results—We enrolled 70 acute TIA patients: 45 intervention and 25 control. The majority of patients had sleep apnea: 57%
at baseline and 59% at 90 days. Among the 30 intervention patients with airflow obstruction, 12 (40%) had acceptable
auto-CPAP adherence, 18 (60%) had some use, and none had no use. Three intervention patients (12%) had recurrent
events compared with 1 (2%; P0.13) control patient. The vascular event rate was highest among sleep apnea patients
with no CPAP use: none, 16%; some, 5%; acceptable adherence 0% (P0.08).
Conclusions—Sleep apnea is common among acute TIA patients. It appears feasible to provide auto-CPAP in the acute
TIA period. Larger studies should evaluate whether a strategy of diagnosing and treating sleep apnea can reduce
recurrent vascular events after TIA. (Stroke. 2010;41:1464-1470.)
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An estimated 300 000 transient ischemic attacks (TIAs)occur annually in the United States.1 TIA patients are at
increased risk of recurrent vascular events; 25% of TIA
patients will have a cerebrovascular or cardiovascular event
or death in the 90 days after TIA, and over the long term, 11%
per year will have a stroke, myocardial infarction, or vascular
death.2–4 Half of the recurrent events occur in the first 2 days
after TIA.3 Given that the recurrent event rate is highest early
after TIA, new interventions are needed that can be applied in
the acute TIA period.
The treatment of sleep apnea may provide a novel thera-
peutic target to improve outcomes for patients with TIA.
Sleep apnea occurs in one in 5 adults in the general popula-
tion5 and in at least 60% of patients with stroke or TIA.6,7
Auto-titrating continuous positive airway pressure (auto-
CPAP) safely and effectively treats sleep apnea.8
The primary objective of this feasibility study was to
evaluate the prevalence of sleep apnea among TIA patients
and the adherence to auto-CPAP among TIA patients with
sleep apnea. The secondary objectives were to compare the
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recurrent vascular event rate among TIA patients according to
an intention-to-treat analysis and among patients with sleep
apnea by auto-CPAP use category. This feasibility trial was
designed as a randomized study of patients with acute TIA,
comparing an intervention group who received a strategy of
diagnosing and treating sleep apnea and a control group who
received diagnostic testing but who did not receive sleep
apnea treatment.
Methods
Sample
TIA patients cared for at 3 hospitals in Connecticut (December 2004
to February 2008) were included if they had a TIA and were 45
years of age. Patients were excluded for a known diagnosis of sleep
apnea, respiratory distress requiring mechanical ventilation, oxygen-
dependent chronic obstructive pulmonary disease, pregnancy, time
from symptom onset to emergency department arrival 72 hours,
life expectancy 6 months, non–English- speaking status, or resi-
dence outside of Connecticut.
Randomization
Patients were randomly assigned to the intervention or control group
in a 1 (control):1.75 (intervention) ratio to ensure a sufficient number
of patients in the intervention group given that a primary outcome
was CPAP adherence. A randomization scheme was developed
before the start of the study. Because patients were often recruited
and randomized in the evening hours, our randomization system
could not involve a call to the coordinating center (which operated
only during regular daytime office hours). For this reason, the
randomization system was converted into a package of sealed
envelopes that the field staff opened in consecutive order. Random-
ization was not stratified by any baseline patient characteristic.
Baseline Measurements
A baseline assessment included a medical record review, an inter-
view of patients or proxies, and physical measurements. The follow-
ing data were collected at baseline: demographics, comorbidities,
medications, blood pressure, heart rate, neck circumference, height,
and weight. The ABCD2 score, a system used to predict short-term
recurrent event rates among patients with TIA, was calculated from:
age (60 years, 1 point); blood pressure (systolic 140 mm Hg or
diastolic 90 mm Hg, 1 point); symptom type (unilateral weakness
with or without speech impairment, 2 points; speech impairment
without weakness, 1 point); symptom duration (60 minutes, 2
points, 10 to 59 minutes, 1 point), and a history of diabetes (1 point).3
The care the patients received to evaluate the etiology of the TIA and
to prevent recurrent vascular events was measured and included the
following: brain imaging, evaluation of the carotid arteries, echocar-
diography use, smoking cessation counseling, antithrombotic medi-
cation use, statin medication use, and angiotensin converting enzyme
inhibitor or angiotensin receptor blocker medication use. Excessive
daytime sleepiness was defined as a score of 10 on the Epworth
Sleepiness Scale.9
Control Group Protocol
Control patients received portable unattended polysomnography at
baseline and at 90 days after TIA (Figure 1). The primary care
providers of the control patients were notified of the polysomnog-
raphy results, but control patients were not given CPAP as part of the
study. Although it was theoretically possible for control patients with
sleep apnea to receive CPAP, none of them actually received CPAP
during the 3-month study period.
Polysomnography was performed by a trained staff member at the
patient’s bedside. The patients were not moved off their unit if they
were admitted to the hospital. The polysomnography included
electroencephalogram, respiratory inductive plethysmography, body
position, ECG, blood pressure, and oxygen saturation.10 We used
portable unattended polysomonography (LifeShirt; Vivometrics) be-
cause it has been validated against the gold standard of polysom-
nography in a sleep laboratory, has been successfully used in clinical
trials of sleep apnea, and can be used throughout the hospital or at a
patient’s residence.11
Diagnosis of Sleep Apnea
Apnea was defined as an airflow cessation of 10 seconds, and
hypopnea was defined as a reduction in airflow of 10 seconds or a
decrease in amplitude of breathing by30%, followed by an oxygen
desaturation of 4%.12–14 The apnea–hypopnea index (AHI) was
calculated from the sum of the number of apneas and hypopneas per
hour of sleep. Sleep apnea was diagnosed when the AHI was 5.13
Intervention Group Protocol
All intervention patients received auto-CPAP. The traditional ap-
proach to the treatment of sleep apnea is to use fixed-pressure CPAP.
This approach requires a 2-step process. First, a sleep study is
performed to diagnose sleep apnea. Then, CPAP titration is per-
formed by a sleep therapist who increases the fixed-pressure CPAP
until the apneas and hypopneas are eliminated. This approach is
usually conducted on 2 nights. In cases in which patients have many
apneas and hypopneas, a split-night study can be conducted in which
both the diagnostic component and the CPAP titration can be
performed on the same evening. Whether or not a split-night study is
performed, the use of fixed-pressure CPAP requires that the patient
have a sleep study in the presence of a sleep technician. Auto-CPAP
machines eliminate respiratory disturbances by varying the pressure
delivered depending on the patients’ respiratory efforts. Auto-CPAP
compared with fixed-pressure CPAP is equally efficacious but has
improved patient adherence and comfort.15,16 We used auto-CPAP
because it is equally as effective as fixed-pressure CPAP and because
it does not require the presence of a sleep therapist for titration.
The auto-CPAP machine (AutoSet Spirit; ResMed) measured and
stored information about respiratory events (apneas and hypopneas),
patient use (minutes used and nights used), mask leak, and
pressure delivered. Auto-CPAP adherence was categorized as no
use, any use (more than no use but 4 hours per night for 75%
of nights), or acceptable adherence (4 hours per night for 75%
of nights).8,17
The machine was interrogated after 2 nights. If there was no
evidence of airflow limitation (AHI 5 or median pressure 6 cm
H2O), then the auto-CPAP was discontinued. If there was evidence
of airflow limitation, then the auto-CPAP was continued for the
remainder of the 90-day period (Figure 1). Intervention patients
received information about sleep apnea, the benefits of CPAP
treatment, and instructions about CPAP machine use daily for 2 days,
weekly for the first month, and then monthly. Research staff made
visits to refit masks or to troubleshoot equipment as needed. Because
polysomnography, and not auto-CPAP, is the gold standard method
of diagnosing sleep apnea, intervention patients received unattended
portable polysomnography at 90 days after TIA (Figure 1).
Figure 1. Research design.
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Outcomes
The primary outcomes were sleep apnea prevalence at baseline
(measured by polysomnography among control patients) and the
proportion of TIA patients with sleep apnea with acceptable auto-
CPAP adherence. The secondary outcome was the 90-day post-TIA
recurrent vascular events rate. Recurrent vascular events included
recurrent TIA, stroke, acute myocardial infarction, hospitalization
for congestive heart failure, and death.2
Adverse Events
All adverse events were reviewed by a panel that included an
internist, a neurologist, and a pulmonologist. The panel classified
each adverse event as serious or nonserious and as related or
unrelated to the study intervention.
Analysis Plan
Descriptive statistics (eg, mean with SDs, medians, and proportions)
were used to describe the baseline characteristics and outcomes. To
compare differences in the outcome rates between control and
intervention patients and among sleep apnea patients with varying
auto-CPAP use,  2 tests or Fisher exact tests were used for binary
or ordinal variables and Student t tests or Wilcoxon rank sum tests
for dimensional variables. Two-sided P values were used to evaluate
differences between the intervention and control groups. A P value
of 0.05 was used to determine statistical significance. An intention-
to-treat analysis was performed comparing the recurrent vascular
event rate among intervention patients compared with control pa-
tients. A secondary prespecified analysis of the recurrent vascular
event rates was conducted among patients with sleep apnea accord-
ing to the amount of auto-CPAP use.
This project was designed to enroll a sufficient number of subjects
to ensure face validity for our feasibility assessments. It was not
powered to identify differences in vascular events between patients
in the intervention versus control groups. No imputations were made
for missing data. All analyses were conducted using SAS 9.1. This
study was registered with clinical trials.gov (NCT00251290) and
was approved by all of the human subject committees of the
participating center.
Results
A total of 360 patients were screened for possible eligibility;
36 did not have a TIA, 6 could not be contacted because
permission to do so was not received by their attending
clinician, 137 patients declined to participate, and 111 met
1 exclusion criterion (Figure 2). A total of 70 patients were
enrolled: 45 intervention and 25 control. Among these, 9 of
45 (20%) were lost to follow-up in the intervention group,
and 5 of 25 (20%) were lost in the control group. Among the
45 intervention patients, 36 used the auto-CPAP machine, 6
of whom had no evidence of airflow obstruction based on the
AHI or the pressure recordings; therefore, they had the CPAP
discontinued, leaving 30 intervention patients eligible for
ongoing CPAP use. Incomplete sleep study data resulted
either from poor quality electroencephalography data or from
patient refusal to perform or complete the sleep study.
Complete unattended polysomnography data were available
in 21 of 25 (84%) control patients at baseline, 16 of 25 (64%)
control patients at 90 days, and 30 of 45 (67%) intervention
patients at 90 days (Figure 2).
Table 1 provides a comparison of baseline characteristics
among the patients in the intervention versus control groups.
Figure 2. Patient screening and recruit-
ment diagram.
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There were no statistically significant differences in the
baseline characteristics of the 2 groups, although the control
patients had higher rates of previous stroke and previous TIA
(Table 1). The majority of patients received auto-CPAP
within 48 hours after the TIA symptom onset: 24 hours, 8
of 45 (18%);2448 hours, 27 of 45 (60%); and48 hours,
10 of 45 (22%). The concomitant care rates were similar
between the 2 groups, although the control patients received
less echocardiography (Table 1).
Sleep Apnea Prevalence
The majority of TIA patients had sleep apnea, both at baseline
(12 of 21 [57%] control patients) and at 90 days (27 of 46
[59%] control and intervention patients; Table 2). The control
and intervention groups had similar rates of sleep apnea based
on polysomnography at 90 days: control, 11 of 16 (69%) and
intervention, 16 of 30 (53%; P0.31).
Among control patients who had complete polysomnogra-
phy data at both baseline and 90 days, 6 of 14 (43%) had
Table 1. Baseline Characteristics (n70)
Characteristic Intervention (n45) Control (n25) P Value*
Age range (y) 47–88 45–88 …
MeanSD 66.311.9 67.412.8 0.73
White race: n (%) 35 (77.8) 16 (64.0) 0.21
Female gender: n (%) 22 (48.9) 13 (52.0) 0.80
Past medical history: n (%)
Hypertension 33 (73.3) 16 (64.0) 0.41
Hyperlipidemia 26 (57.8) 10 (40.0) 0.15
Diabetes mellitus 15 (33.3) 6 (24.0) 0.41
Stroke 7 (15.6) 5 (20.0) 0.74
TIA 7 (15.6) 7 (28.0) 0.23
Atrial fibrillation 6 (13.3) 1 (4.0) 0.41
Myocardial infarction 5 (11.1) 1 (4.0) 0.41
Congestive heart failure 3 (6.7) 1 (4.0) 1.00
Chronic obstructive pulmonary disorder 2 (4.4) 0 (0) 0.53
Current tobacco smoking: n (%) 2 (8.0) 8 (17.8) 0.48
Blood pressure (mm Hg): meanSD
Systolic 140.321.8 142.016.9 0.75
Diastolic 78.312.5 82.111.5 0.21
Neck circumference (inches): meanSD 15.61.2 15.31.4 0.40
Waist circumference (inches): meanSD 41.23.4 40.35.5 0.48
Weight (pounds): meanSD 179.527.5 178.742.8 0.94
Body mass index (kg/m2): meanSD 28.64.1 27.86.5 0.59
Excessive daytime sleepiness: n (%) 17 (37.8) 7 (28.0) 0.41
ABCD2 score 1.671.0 1.720.94 0.96
Symptom duration: meanSD 3.95.3 4.37.8 0.79
Time from symptom onset to CPAP or sleep study (hours)
MeanSD 39.423.7 45.037.1 0.50
24 hours: n (%) 8 (18) 4 (16) …
24 hours, 48 hours: n (%) 27 (60) 15 (60) …
48 hours: n (%) 10 (22) 6 (24) …
Concomitant care: n (%)
Admission brain imaging received 45 (100) 25 (100) 1.00
Antithrombotic therapy 40 (89) 24 (96) 0.41
Smoking cessation counseling for smokers 4/5 (80) 0/2 (0) 0.14
Carotid imaging received 37 (82) 17 (68) 0.17
ACEI/ARB medication received 23 (51) 11 (44) 0.57
Statin medication received 23 (51) 10 (40) 0.46
Echocardiography received 42 (93) 19 (76) 0.06
*P values refer to 2-sided P values obtained from Student t tests, Wilcoxon tests, 2 tests, or Fisher exact tests.
The ABCD2 score is used to predict short-term recurrent event rates among patients with TIA.
ACEI/ARB refers to an angiotensin converting enzyme inhibitor or receptor blocking medication.
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sleep apnea at both time points, 2 of 14 (14%) did not have
sleep apnea at both time points, 4 of 14 (29%) had no sleep
apnea in the acute TIA period but sleep apnea present after 90
days, and 2 of 14 (14%) had sleep apnea in the acute TIA
period but not after 90 days. Therefore, in 8 of 14 (57%)
patients, their diagnostic categorization was stable, but in 6 of
14 (43%) patients, their diagnostic categorization changed
from the acute TIA period to 90 days after TIA. The AHI
from the acute TIA period ranged from 0.5 to 36.7 among
patients with stable diagnoses and from 0.0 to 7.5 among
patients with a change in diagnosis. Therefore, an AHI of
7.5 could be used to identify patients who are unlikely to
change their diagnostic category.
Among the 30 intervention patients with complete polysom-
nography and auto-CPAP data, the diagnostic agreement was
agreement in 15 of 27 (55%) patients, with a positive predictive
value of 55% and a negative predictive value of 57%.
Auto-CPAP Use
Among the 30 intervention patients who had evidence of
airflow obstruction based on data from the auto-CPAP
machine, acceptable adherence was observed in 12 (40%),
some use in 18 (60%), and none with no use (Table 3).
Recurrent Vascular Events
When examining the effect of auto-CPAP on the recurrent
vascular event rate according to an intention-to-treat analysis
(including both patients with and without sleep apnea and
including patients in the intervention group who did not use
CPAP), we observed that 3 of 25 (12%) of control patients
had a recurrent vascular event compared with 1 of 45 (2%) of
intervention patients (P0.13; Table 4). Among patients with
sleep apnea at baseline, the recurrent vascular event rate was
highest among patients with no CPAP use: no use, 1 of 12
(8%); some use, 1 of 18 (6%); acceptable adherence, 0 of 12
(0%; P0.34; Table 4). Among patients with any evidence of
sleep apnea, either from the auto-CPAP machine or from
unattended polysomnography at baseline or at 90 days after
TIA (this approach allows for the classification of the most
number of patients because it uses all possible data), the
recurrent vascular event rate was highest among patients with
no CPAP use: no use, 3 of 19 (16%); some use, 1 of 21 (5%);
acceptable adherence, 0 of 13 (0%; P0.08).
Adverse Events
Serious adverse events were observed among 4 of 25 (16.0%)
control patients and 7 of 45 (15.6%) intervention patients
(P1.0). The 4 serious events among the control group
included a new stroke in 2 patients and recurrent TIAs in 2
patients. The serious events among the 7 intervention patients
included a new stroke in 2 patients, a hospitalization for atrial
fibrillation complicated by hypotension in 1 patient, a hospi-
talization for hyperglycemia in 1 patient, a hospitalization for
hypoglycemic in 1 patient, 1 patient who was hospitalized
once for congestive heart failure and once with dehydration,
and 1 patient who was hospitalized for acute renal failure and
also for radiotherapy for cancer. No serious adverse events
were related to the intervention.
Nonserious adverse events were observed among 1 of 25
(4.0%) control patients and 5 of 45 (11.1%) intervention
patients (P0.41). The nonserious adverse events related to
the study intervention included skin irritation from the mask
(n2) and sneezing/nasal irritation because of the CPAP
(n2).
Discussion
Our findings indicate that sleep apnea is common among this
selected group of acute TIA patients, and that it is feasible to
implement a strategy of using auto-CPAP in the acute TIA
period to diagnose and treat sleep apnea. The recurrent
vascular event rate seen in this cohort of TIA patients (12%
among the controls) was lower than the expected 25% event
rate.2–4 This study was designed to assess the feasibility of
diagnosing and treating sleep apnea among patients with
acute TIA. The study was designed to have adequate sample
size and therefore adequate statistical power to address the
feasibility aims; it was not designed to have adequate power
to evaluate the efficacy of auto-CPAP in the prevention of
recurrent vascular events among post-TIA patients. Although
the recurrent event rate was lower among intervention pa-
tients in this study, this difference did not reach statistical
Table 2. Prevalence of Sleep Apnea*
Characteristic Baseline (n21) 90-Day (n46)
AHI range 0–36.7 0–61.6
MeanSD 11.111.7 11.013.2
Sleep apnea prevalence n (%) 12 of 21 (57) 27 of 46 (59)
Central event AHI: range 0–1.6 0–35.3†
MeanSD 0.410.59 1.887.36
Total sleep time (hours:minutes): range 1:10–9:16 0:46–10:48
MeanSD 5:512:33 5:601:54
Mean oxygenation (%): range 92–97 90–98
MeanSD 94.41.6 94.71.6
Oxygen desaturation index 4% 0.2–16.8 0–54.8
MeanSD 3.44.8 3.58.1
*The prevalence of sleep apnea is based on polysomnography data. The
diagnosis of sleep apnea was made if the AHI was 5.
†We observed frequent central events in only 1 intervention patient with
severe sleep apnea (AHI 61.6) who also had frequent obstructive events.
Table 3. Auto-CPAP Use
Auto-CPAP Use Category Eligible Intervention Patients* (n30)
Proportion of nights used: range 0.02–0.88
MeanSD 0.470.33
No. of hours/night CPAP used:
range (hours)
1.5–8.5
MeanSD 5.61.9
CPAP use: n (%) …
None: 0 nights or 0 hours/night 0 (0)
Some: 70% nights for 4
hours/night
18 (60)
Excellent: 70% nights for 4
hours/night
12 (40)
*Eligible intervention patients included the 30 patients who had evidence of
sleep apnea from the auto-CPAP machine.
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significance, perhaps because this study was not powered to
detect this difference.
The prevalence of sleep apnea observed in this study is
similar to rates observed in previous studies.6,7 For example,
Parra et al studied 39 TIA patients and found that 62% had
sleep apnea based on an AHI of 10.6 Moreover, we found
that although the overall prevalence remains fairly stable over
the first 3 months after TIA (acute, 57% versus 90 days,
59%), the diagnostic categorization of an individual patient
may shift from the acute TIA period to the 90-day period. Our
results indicate that an AHI of7.5 can identify patients with
sleep apnea in the acute TIA period who will continue to have
sleep apnea after 90 days.
The auto-CPAP use observed in this study was similar to
some previous reports in non-TIA patients but higher than
those several reported studies of CPAP use among patients
with stroke.7,18,19 It may be that TIA patients have higher
adherence than stroke patients because TIA patients do not
have neurological impairments that could interfere with
regular CPAP use. We might also have observed a higher
adherence because our study staff visited with patients to
encourage auto-CPAP use and to help patients overcome any
difficulties they may have experienced with the equipment.
The auto-CPAP use analysis excluded patients who did not
have sleep apnea and patients who withdrew from the study;
this approach increases the relative adherence rate but is the
standard analytic practice.7 The 20% withdrawal rate among
intervention patients serves to potentially bias our results in
favor of reporting a relatively higher auto-CPAP adherence.
Despite this limitation, the adherence that was observed was
better than expected given that a small minority of patients
were symptomatic with excessive daytime sleepiness.
Despite a lower-than-expected recurrent vascular event
rate, our finding that increasing auto-CPAP use was associ-
ated with a lowered recurrent vascular event rate (albeit not
statistically significantly so) is consistent with the findings of
Martinez-Garcia et al, who found among patients distant from
a stroke or TIA that the recurrent vascular event rate was 7%
among CPAP users (n15) and 36% among patients without
CPAP use (n36; P0.03).19 The mechanisms by which
CPAP may reduce recurrent vascular events after TIA are
unknown but may include lowering blood pressure, improv-
ing oxygenation, decreasing platelet activation, improved
left-ventricular ejection fraction, which may contribute to
improve cerebral perfusion, or lowering fibrinogen.20–22 Fu-
ture studies should confirm the effectiveness of CPAP in the
acute TIA period and should also be directed at examining the
mechanism by which CPAP may improve outcomes. Future
trials that evaluate post-TIA interventions should design their
sample size with the 12% event rate we observed (as opposed
to the 25% event rate described in cohort studies).2–4
One noteworthy aspect of this research design is the
application of an intervention not based on patient symptoms
but rather based on estimated disease prevalence within a
group. Specifically, we did not provide the intervention
strategy only to patients with daytime sleepiness or other
symptoms consistent with sleep apnea, but rather provided
the intervention to all stroke patients randomized to the
intervention group. The rationale for this approach was based
on the previous literature6,7 that has demonstrated that sleep
apnea is common among TIA patients, the safety profile of
the intervention in routine clinical practice, and the need to
provide treatment as early as possible in the acute TIA period
to achieve maximal benefit. Our findings suggest that this
approach is feasible and may improve patient outcomes. An
alternative research design would have been to use sham
CPAP for patients randomized to the control arm. Sham
CPAP was not used in this study because the “usual care”
control arm approach provided a scientifically sound com-
parison while enhancing the feasibility of conducting the
study and ensuring patient safety.
Future studies are needed to answer several key questions
that relate to the implementation of this strategy within
routine clinical practice: is there a group of patients for whom
the auto-CPAP intervention is most beneficial and a group for
whom it is unlikely to be helpful? how long should the
auto-CPAP be continued? at what point, if ever, should a
formal polysomnography be performed? and for TIA patients
who nap during the day and sleep at night, should the
auto-CPAP be used both during the day and at night?
The primary strength of the design of this study was that it
was a randomized controlled comparison of usual care versus
a strategy of diagnosing and treating sleep apnea in the acute
TIA period. We sought to include a broad range of patients to
enhance the generalizability of these findings. Despite these
strengths, the following limitations require attention. First,
although the patients were recruited from a Department of
Veterans Affairs medical center, a large tertiary care center, a
moderately large community hospital, and physician offices
in one county, these findings should be replicated in a larger
multisite study that is powered to detect differences in the
recurrent vascular event rate.
Second, we used an approach using auto-CPAP early
post-TIA without first using diagnostic polysomnography.
We found relatively poor diagnostic agreement between the
auto-CPAP machine and the polysomnography (55% agree-
ment). This strategy provides for the earliest possible admin-
istration of auto-CPAP therapy. Given the safety of auto-
Table 4. Recurrent Vascular Events
Overall (Intention-to-Treat) n70
Sleep Apnea† (by Auto-CPAP Use
Category) n42
Outcome Control (n25) Intervention (n45) P Value None (n12) Some (n18) Acceptable (n12)
Vascular events 3 (12) 1 (2) 0.13 1 (8) 1 (6) 0 (0)
Vascular events included recurrent TIAs, stroke, myocardial infarction, hospitalization for congestive heart failure, or any death.
†The adherence analysis only included sleep apnea patients, including 12 control patients in the “none” group.
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CPAP and the relatively high prevalence of sleep apnea, this
approach is likely to provide the earliest treatment to the
largest number of patients with low risk of harm. Future
studies will have to address the issue of whether auto-CPAP
is beneficial to patients despite this diagnostic inaccuracy.
Third, although the losses to follow-up were equal in both
groups, 20% losses in each arm was higher than we expected.
Any conclusions drawn from this study must be made in the
context of this withdrawal rate.
Despite these limitations, these research findings suggest
that the strategy of diagnosis and treating sleep apnea among
selected acute TIA patients may be a novel therapeutic
strategy to improve patient outcomes. Future studies are
needed to confirm these findings. Given that no specialized
systems are needed to implement CPAP therapy, this inter-
vention may have the potential to be applicable to most TIA
patients regardless of the size or complexity of the facility
where they receive their care.
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Abstract
应用自动调节连续气道正压通气治疗急性短暂性脑缺血发作患者
一项随机对照可行性试验
Auto-Titrating Continuous Positive Airway Pressure for Patients With 
Acute Transient Ischemic Attack  
 A Randomized Feasibility Trial
Dawn M. Bravata, MD; John Concato, MD; Terri Fried, MD; Noshene Ranjbar, MD; Tanesh Sadarangani, MD; 
Vincent McClain, MD; Frederick Struve, PhD; Lawrence Zygmunt, BA; Herbert J. Knight, MD; Albert Lo, MD, PhD; 
George B. Richerson, MD, PhD; Mark Gorman, MD; Linda S. Williams, MD; Lawrence M. Brass, MD; 
Joseph Agostini, MD; Vahid Mohsenin, MD; Francoise Roux, MD, PhD; H. Klar Yaggi, MD, MPH
背景和目的：短暂性脑缺血发作 (TIA) 患者存在再发血管事件的风险。本研究主要观察目标是评价 TIA 患者中睡眠呼吸
暂停的患病率，以及睡眠呼吸暂停患者进行自动调节连续气道正压通气 (auto-CPAP) 治疗的依从性。次要观察目标是描
述在具有睡眠呼吸暂停的 TIA 患者中，应用 auto-CPAP 治疗的亚组再发血管事件的比率。
方法：所有入选的 TIA 患者被随机分为干预组及对照组。干预组患者均接受两晚的 auto-CPAP 治疗，对其中存在睡眠呼
吸暂停的亚组患者延续治疗至 90 天。所有干预组患者在 TIA 后 90 天行多导睡眠描记仪检测。对照组患者则仅在基线和
TIA 后 90 天时进行多导睡眠描记仪检测，并不接受 auto-CPAP 治疗。良好依从 auto-CPAP 治疗的定义为总监测时间内至
少有 75% 的夜间使用了 auto-CPAP 治疗，并且每晚至少使用 4 小时。血管事件包括再发 TIA、卒中、需住院治疗 ( 或死亡 )
的充血性心力衰竭、心肌梗死。
结果：本研究共纳入 70 例急性 TIA 患者：45 例干预组和 25 例对照组。大多数患者存在睡眠呼吸暂停：基线为 57%，
TIA 后 90 天为 59%。在 30 例具有气流阻塞的干预组亚组患者中，12 例患者 (40%) 良好依从了 auto-CPAP 治疗，18 例
患者 (60%) 为部分使用，并无患者从未使用过。对照组及干预组分别有 3 例 (12%) 和 1 例 (2%，P=0.13) 患者再发了血管
性事件。存在睡眠呼吸暂停并且未接受 auto-CPAP 治疗的患者，血管事件再发率最高：从未使用、部分使用及良好依从
auto-CPAP 治疗的患者血管事件再发率分别为 16%、5% 和 0% (P=0.08)。
结论：急性 TIA 患者常存在睡眠呼吸暂停现象。在 TIA 的急性期给予 auto-CPAP 治疗是可行的。仍需要大样本研究进一
步评价睡眠呼吸暂停的诊治是否可减少 TIA 后再发血管事件。 
关键词：睡眠障碍，短暂性脑缺血发作，治疗
(Stroke. 2010;41:1464-1470.　孙海欣 译  王文志 校 )
表 3　Auto-CPAP 的使用情况
Auto-CPAP 的使用情况分类 符合干预标准的患者 * (n=30)
夜间使用比率：范围 0.02-0.88
　均数±标准差 0.47±0.33
使用 CPAP 治疗的小时数 / 晚：范围 ( 小时 ) 1.5-8.5
　均数±标准差 5.6±1.9
使用 CPAP ：例数 (%) …
　从未使用过：0 次夜间使用或 0 小时 / 晚 0 (0%)
　部分使用：<70% 夜间使用，<4 小时 / 晚 18 (60%)
　良好依从：≥ 70% 夜间使用，≥ 4 小时 / 晚 12 (40%)
* 符合干预标准的 30 例患者为使用 auto-CPAP 治疗并存在明确的睡眠呼吸暂停者。
